Ketoconazole in the prevention of experimental candidal vaginitis.
The prophylactic and therapeutic activities of ketoconazole were evaluated in rats inoculated intravaginally with Candida albicans. Daily doses of 2.5 mg/kg initiated 48 h before challenge and continued for 48 h thereafter protected 80% of the rats against infection. A similar result in rats with established infection was attained with daily doses of 5.0 mg/kg.
D000818:Animals; D002181:Candidiasis, Vulvovaginal / Q000517:prevention & control*; D002369:Castration; D005260:Female; D007654:Ketoconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D010053:Ovary / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains
D007654:Ketoconazole